218 related articles for article (PubMed ID: 23821578)
21. Volume of Gleason pattern 4 stratifies risk of metastasis and death in patients with Gleason score 3+5=8/5+3=8 positive prostate core biopsies.
Acosta AM; Taplin ME; Mata DA; D'Amico AV; Hirsch MS
Hum Pathol; 2020 May; 99():62-74. PubMed ID: 32171650
[TBL] [Abstract][Full Text] [Related]
22. Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical Prostatectomy.
Jang WS; Kim LH; Yoon CY; Rha KH; Choi YD; Hong SJ; Ham WS
PLoS One; 2016; 11(10):e0164497. PubMed ID: 27716842
[TBL] [Abstract][Full Text] [Related]
23. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
24. Salvage radiation therapy for prostate cancer patients after prostatectomy.
Mima T; Ohori M; Hirasawa Y; Mikami R; Arai A; Hashimoto T; Satake N; Gondo T; Nakagami Y; Namiki K; Tokuuye K; Ohno Y
Jpn J Clin Oncol; 2019 Mar; 49(3):281-286. PubMed ID: 30608594
[TBL] [Abstract][Full Text] [Related]
25. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
[TBL] [Abstract][Full Text] [Related]
26. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.
Ying J; Wang CJ; Yan J; Liauw SL; Straka C; Pistenmaa D; Xie XJ; Lotan Y; Roehrborn C; Kim DN
Am J Clin Oncol; 2017 Dec; 40(6):612-620. PubMed ID: 26165416
[TBL] [Abstract][Full Text] [Related]
27. Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model.
Taguchi S; Uemura Y; Fujimura T; Morikawa T; Naito A; Kawai T; Suzuki M; Kume H; Fukuhara H
BMC Cancer; 2020 May; 20(1):371. PubMed ID: 32357849
[TBL] [Abstract][Full Text] [Related]
28. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.
Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Polkinghorn W; McBride S; Kollmeier M; Yamada Y; Zelefsky MJ
Eur Urol; 2015 Jun; 67(6):1009-1016. PubMed ID: 25308970
[TBL] [Abstract][Full Text] [Related]
29. Primary Gleason pattern in biopsy Gleason score 7 is predictive of adverse histopathological features and biochemical failure following radical prostatectomy.
Berg KD; Røder MA; Brasso K; Vainer B; Iversen P
Scand J Urol; 2014 Apr; 48(2):168-76. PubMed ID: 23889119
[TBL] [Abstract][Full Text] [Related]
30. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
[TBL] [Abstract][Full Text] [Related]
31. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.
Tumati V; Jackson WC; Abugharib AE; Raj G; Roehrborn C; Lotan Y; Courtney K; Bagrodia A; Gahan JC; Zumsteg ZS; Folkert MR; Laine AM; Hannan R; Spratt DE; Desai NB
BJU Int; 2018 Mar; 121(3):365-372. PubMed ID: 28581200
[TBL] [Abstract][Full Text] [Related]
32. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
[TBL] [Abstract][Full Text] [Related]
33. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
Feng FY; Huang HC; Spratt DE; Zhao SG; Sandler HM; Simko JP; Davicioni E; Nguyen PL; Pollack A; Efstathiou JA; Dicker AP; Todorovic T; Margrave J; Liu YS; Dabbas B; Thompson DJS; Das R; Dignam JJ; Sweeney C; Attard G; Bahary JP; Lukka HR; Hall WA; Pisansky TM; Shah AB; Pugh SL; Shipley WU; Tran PT
JAMA Oncol; 2021 Apr; 7(4):544-552. PubMed ID: 33570548
[TBL] [Abstract][Full Text] [Related]
34. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
35. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
36. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
[TBL] [Abstract][Full Text] [Related]
37. Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis.
Spratt DE; Zumsteg Z; Ghadjar P; Pangasa M; Pei X; Fine SW; Yamada Y; Kollmeier M; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1254-61. PubMed ID: 23182392
[TBL] [Abstract][Full Text] [Related]
38. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
39. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
[TBL] [Abstract][Full Text] [Related]
40. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
